Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Role of [18F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [11C]Choline PET/CT and Histopathological Analysis.
Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone CV, Nanni C, Bossert I, Matti A, Schiavina R, Fiorentino M, Fonti C, Lodi F, D'Errico A, Brunocilla E, Fanti S. Zanoni L, et al. Among authors: pultrone cv. Cancers (Basel). 2021 Mar 29;13(7):1575. doi: 10.3390/cancers13071575. Cancers (Basel). 2021. PMID: 33805543 Free PMC article.
[18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial.
Zanoni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, Matti A, Schiavina R, Fiorentino M, Romagnoli D, Fonti C, Lodi F, D'Errico A, Brunocilla E, Porreca A, Fanti S. Zanoni L, et al. Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):390-409. doi: 10.1007/s00259-021-05429-6. Epub 2021 Jul 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 34213609 Clinical Trial.
Preoperative Staging With 11C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer.
Schiavina R, Bianchi L, Mineo Bianchi F, Borghesi M, Pultrone CV, Dababneh H, Castellucci P, Ceci F, Nanni C, Gaudiano C, Fiorentino M, Porreca A, Chessa F, Minervini A, Fanti S, Brunocilla E. Schiavina R, et al. Among authors: pultrone cv. Clin Genitourin Cancer. 2018 Aug;16(4):305-312.e1. doi: 10.1016/j.clgc.2018.05.010. Epub 2018 May 30. Clin Genitourin Cancer. 2018. PMID: 29859737
(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, Malizia C, Ferrari M, Rigatti P, Fonti C, Martorana G, Fanti S. Nanni C, et al. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10. Eur J Nucl Med Mol Imaging. 2016. PMID: 26960562 Clinical Trial.
Metabolic Imaging in Prostate Cancer: Where We Are.
Testa C, Pultrone C, Manners DN, Schiavina R, Lodi R. Testa C, et al. Front Oncol. 2016 Nov 9;6:225. doi: 10.3389/fonc.2016.00225. eCollection 2016. Front Oncol. 2016. PMID: 27882307 Free PMC article. Review.
Adverse Features and Competing Risk Mortality in Patients With High-Risk Prostate Cancer.
Vagnoni V, Bianchi L, Borghesi M, Pultrone CV, Dababneh H, Chessa F, La Manna G, Rizzi S, Porreca A, Brunocilla E, Martorana G, Schiavina R. Vagnoni V, et al. Among authors: pultrone cv. Clin Genitourin Cancer. 2017 Apr;15(2):e239-e248. doi: 10.1016/j.clgc.2016.08.016. Epub 2016 Aug 25. Clin Genitourin Cancer. 2017. PMID: 27641658
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial.
Schiavina R, Droghetti M, Novara G, Bianchi L, Gaudiano C, Panebianco V, Borghesi M, Piazza P, Mineo Bianchi F, Guerra M, Corcioni B, Fiorentino M, Giunchi F, Verze P, Pultrone C, Golfieri R, Porreca A, Mirone V, Brunocilla E. Schiavina R, et al. Urol Oncol. 2021 Jul;39(7):433.e1-433.e7. doi: 10.1016/j.urolonc.2020.10.018. Epub 2020 Nov 13. Urol Oncol. 2021. PMID: 33191117 Clinical Trial.
42 results